• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by AIkido Pharma Inc.

    6/14/22 6:01:24 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary
    Get the next $AIKI alert in real time by email
    SC 13G 1 ea161537-13gintra_aikido.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.    )*

     

    AIkido Pharma Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

     

    (Title of Class of Securities)

     

    008875106

     

    (CUSIP Number)

     

    June 7, 2022

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.  ☐ Rule 13d-1(b)
    b.  ☒ Rule 13d-1(c)
    c.  ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.

    008875106

     

     

     

     

    1. Names of Reporting Persons.
       
      Mitchell P. Kopin
         
         
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a)
      (b)
         
         
    3. SEC Use Only
         
         
    4. Citizenship or Place of Organization United States of America
         

         
    Number of 5.  Sole Voting Power 0
    Shares Beneficially    
    Owned by Each    
    Reporting 6.  Shared Voting Power

    149,805

    Person With:    
         
    7.  Sole Dispositive Power 0
         
         
      8.  Shared Dispositive Power

    159,805

         

         
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 159,805 (see Item 4)
         
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
         
         
    11. Percent of Class Represented by Amount in Row (9) 3.0% (see Item 4)
         
         
    12. Type of Reporting Person (See Instructions)  
         
      IN; HC  
         

    Page 2 of 8

     

     

    CUSIP No.

    008875106

     

     

     

     

    1. Names of Reporting Persons.
       
      Daniel B. Asher
         
         
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a)
      (b)
         
         
    3. SEC Use Only
         
         
    4. Citizenship or Place of Organization United States of America
         

         
    Number of 5.  Sole Voting Power 56,263
    Shares Beneficially    
    Owned by Each    
    Reporting 6.  Shared Voting Power

    149,805

    Person With:    
         
    7.  Sole Dispositive Power 63,277
         
         
      8.  Shared Dispositive Power

    159,805

         

         
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 223,082 (see Item 4)
         
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
         
         
    11. Percent of Class Represented by Amount in Row (9) 4.2% (see Item 4)
         
         
    12. Type of Reporting Person (See Instructions)  
         
      IN; HC  
         

    Page 3 of 8

     

     

    CUSIP No.

    008875106

     

     

     

     

    1. Names of Reporting Persons.
       
      Intracoastal Capital LLC
         
         
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a)
      (b)
         
         
    3. SEC Use Only
         
         
    4. Citizenship or Place of Organization Delaware
       

         
    Number of 5.  Sole Voting Power 0
    Shares Beneficially    
    Owned by Each    
    Reporting 6.  Shared Voting Power

    149,805

    Person With:    
         
    7.  Sole Dispositive Power 0
         
         
      8.  Shared Dispositive Power

    159,805

         

         
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 159,805 (see Item 4)
         
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
         
         
    11. Percent of Class Represented by Amount in Row (9) 3.0% (see Item 4)
         
         
    12. Type of Reporting Person (See Instructions)  
         
      OO  
         

    Page 4 of 8

     

    Item 1.

     

    (a)Name of Issuer

     

    AIkido Pharma Inc. (the “Issuer”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    One Rockefeller Plaza, 11th Floor

    New York, NY 10020

     

    Item 2.

     

    (a)Name of Person Filing
    (b)Address of Principal Business Office or, if none, Residence
    (c)Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

     

    The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

     

    (d)Title of Class of Securities

     

    Common Stock, $0.0001 par value per share, of the Issuer (the “Common Stock”).

     

    (e)CUSIP Number

     

    008875106

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4. Ownership.

     

    (a)and (b):

     

    (i) As of the close of business on June 7, 2022, each of Intracoastal and Mr. Kopin may have been deemed to have beneficial ownership of 567,981 shares of Common Stock, which consisted of (i) 135,035 shares of Common Stock held by Intracoastal, (ii) 279,412 shares of Common Stock issuable upon conversion of shares of Series O Redeemable Convertible Preferred Stock, $0.0001 par value per share, of the Issuer (the “Series O Preferred Stock”), (iii) 7,738 shares of Common Stock issuable upon an exercise of a warrant held by Intracoastal (the “Intracoastal Warrant”) and (iv) 145,796 shares of Common Stock issuable upon conversion of shares of Series P Redeemable Convertible Preferred Stock, $0.0001 par value per share, of the Issuer (the “Series P Preferred Stock”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 5,252,556 shares of Common Stock outstanding as of May 16, 2022 as reported by the Issuer and as adjusted for the stock combination effected by the Issuer on June 7, 2022, plus (2) 279,412 shares of Common Stock issuable upon conversion of shares of Series O Preferred Stock, (3) 7,738 shares of Common Stock issuable upon an exercise of the Intracoastal Warrant and (4) 145,796 shares of Common Stock issuable upon conversion of shares of Series P Preferred Stock. The foregoing excludes 133,616 shares of Common Stock issuable upon conversion of shares of Series P Preferred Stock because the Series P Preferred Stock contains a blocker provision under which the holder thereof does not have the right to convert the Series P Preferred Stock to the extent (but only to the extent) that such conversion would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 701,597 shares of Common Stock.

     

    Page 5 of 8

     

      

    As of the close of business on June 7, 2022, Mr. Asher may have been deemed to have beneficial ownership of 561,870 shares of Common Stock, which consisted of (i) 135,035 shares of Common Stock held by Intracoastal, (ii) 55,064 shares of Common Stock held by Mr. Asher, (iii) 279,412 shares of Common Stock issuable upon conversion of shares of Series O Preferred Stock, (iv) 7,738 shares of Common Stock issuable upon an exercise of the Intracoastal Warrant and (v) 84,621 shares of Common Stock issuable upon conversion of shares of Series P Preferred Stock, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 5,252,556 shares of Common Stock outstanding as of May 16, 2022 as reported by the Issuer and as adjusted for the stock combination effected by the Issuer on June 7, 2022, plus (2) 279,412 shares of Common Stock issuable upon conversion of shares of Series O Preferred Stock, (3) 7,738 shares of Common Stock issuable upon an exercise of the Intracoastal Warrant and (4) 84,621 shares of Common Stock issuable upon conversion of shares of Series P Preferred Stock. The foregoing excludes 194,791 shares of Common Stock issuable upon conversion of shares of Series P Preferred Stock because the Series P Preferred Stock contains a blocker provision under which the holder thereof does not have the right to convert the Series P Preferred Stock to the extent (but only to the extent) that such conversion would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 756,661 shares of Common Stock.

     

    (ii) As of the close of business on June 13, 2022, each of Intracoastal and Mr. Kopin may have been deemed to have beneficial ownership of 159,805 shares of Common Stock, which consisted of (i) 152,067 shares of Common Stock held by Intracoastal and (ii) 7,738 shares of Common Stock issuable upon exercise of the Intracoastal Warrant, and all such shares of Common Stock represented beneficial ownership of approximately 3.0% of the Common Stock, based on (1) 5,252,556 shares of Common Stock outstanding as of May 16, 2022 as reported by the Issuer and as adjusted for the stock combination effected by the Issuer on June 7, 2022, plus (2) 7,738 shares of Common Stock issuable upon exercise of the Intracoastal Warrant.

     

    As of the close of business on June 13, 2022, Mr. Asher may have been deemed to have beneficial ownership of 223,082 shares of Common Stock, which consisted of (i) 152,067 shares of Common Stock held by Intracoastal, (ii) 63,277 shares of Common Stock held by Mr. Asher and (iii) 7,738 shares of Common Stock issuable upon exercise of the Intracoastal Warrant, and all such shares of Common Stock represented beneficial ownership of approximately 4.2% of the Common Stock, based on (1) 5,252,556 shares of Common Stock outstanding as of May 16, 2022 as reported by the Issuer and as adjusted for the stock combination effected by the Issuer on June 7, 2022, plus (2) 7,738 shares of Common Stock issuable upon exercise of the Intracoastal Warrant.

     

    (c)

    Number of shares as to which each of Intracoastal and Mr. Kopin has:

     

    (i) Sole power to vote or to direct the vote:      0      .

     

    (ii) Shared power to vote or to direct the vote: 149,805 .

     

    (iii) Sole power to dispose or to direct the disposition of       0     .

     

    (iv) Shared power to dispose or to direct the disposition of 159,805 .

     

    Number of shares as to which Mr. Asher has:

     

    (i) Sole power to vote or to direct the vote: 56,263 .

     

    (ii) Shared power to vote or to direct the vote: 149,805 .

     

    (iii) Sole power to dispose or to direct the disposition of 63,277 .

     

    (iv) Shared power to dispose or to direct the disposition of 159,805 .

     

    Page 6 of 8

     

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 7 of 8

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: June 14, 2022

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin

     

      /s/ Daniel B. Asher
      Daniel B. Asher

     

      Intracoastal Capital LLC
       
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

     

    Page 8 of 8

     

    Get the next $AIKI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIKI

    DatePrice TargetRatingAnalyst
    10/11/2021$2.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AIKI
    SEC Filings

    View All

    AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update

    8-K - Dominari Holdings Inc. (0000012239) (Filer)

    12/18/23 4:05:35 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update

    8-K - Dominari Holdings Inc. (0000012239) (Filer)

    11/13/23 6:05:12 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 10-Q filed by AIkido Pharma Inc.

    10-Q - Dominari Holdings Inc. (0000012239) (Filer)

    11/6/23 4:47:02 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    $AIKI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dominari Holdings Provides Update on Share Repurchase Program

    NEW YORK, Dec. 28, 2022 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today provided an update on the $2 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on December 5, 2022. The Company reported that on December 27, 2022, the Company purchased 4,000 shares of common stock at $3.1012 per share. Anthony Hayes, CEO of Dominari, stated, "The Company's stock is trading at levels we believe are below its intrinsic value. To enhance shareholder value, we are making purchases as part

    12/28/22 9:00:00 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH)

    NEW YORK, Dec. 22, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) (the "Company") today announced that it has changed its name from AIkido Pharma Inc. to Dominari Holdings Inc. and its ticker symbol from "AIKI" to "DOMH." The Company expects that its shares of common stock will begin trading on The Nasdaq Stock Market under the new name and new stock ticker symbol "DOMH" on or about December 22, 2022. The name change was approved at a meeting of the board of directors held on December 5, 2022. Anthony Hayes, CEO of Dominari Holdings Inc., commented, "Rebranding of the C

    12/22/22 8:00:00 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes

    Leading Advanced Materials Company Now Listed on NASDAQ under the symbol, ASPI NEW YORK, Nov. 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI"). ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses. The shares began trading on the Nasdaq Capita

    11/28/22 9:00:00 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    $AIKI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/28/23 8:00:33 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/28/23 8:00:36 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    Hayes Anthony bought $140,168 worth of shares (70,000 units at $2.00) (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/22/23 6:00:41 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    $AIKI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/28/23 8:00:33 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/28/23 8:00:36 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    Wool Kyle Michael was granted 630,050 shares, increasing direct ownership by 77% to 1,448,908 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/26/23 6:43:23 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    $AIKI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on AIkido Pharma with a new price target

    HC Wainwright & Co. initiated coverage of AIkido Pharma with a rating of Buy and set a new price target of $2.00

    10/11/21 6:14:44 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    $AIKI
    Financials

    Live finance-specific insights

    View All

    AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease

    NEW YORK, June 23, 2021 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced that the Company has filed a provisional patent application for the use of ketamine and peptides to treat Alzheimer's disease.  The Company previously secured and announced the acquisition of patent rights for use of peptides as a drug delivery system.  This patent application seeks patent protection for the use of ketamine and these peptides to treat Alzheimer's disease. We believe that one of the biggest breakthroughs in the study of depression has been the ob

    6/23/21 10:00:00 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    $AIKI
    Leadership Updates

    Live Leadership Updates

    View All

    AIkido Pharma Inc. Appoints New Director, Soo Yu

    New Director Supports NASDAQ Rule on Diversity NEW YORK, June 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the appointment of Ms. Soo Yu, as a director of the Company.  Anthony Hayes, CEO of AIkido stated, "At the time of the annual meeting, there was concern expressed by some shareholders about the Company's compliance with the new NASDAQ rules on diversity.  The Company strongly believes in diversity and Ms. Yu is an exceptional candidate that also satisfies the new NASDAQ rule.  Further, Ms. Yu's background broadens t

    6/10/22 4:15:00 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    AIkido Pharma Releases Shareholder Update; Near Term Catalysts Approaching

    NEW YORK, Sept. 14, 2021 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today released the following shareholder update: Dear Shareholder, September is an opportune time to provide a shareholder and investor update and we are pleased to report on positive developments and near-term upcoming potential value creating catalysts. To start, we are pleased to announce that last month, DatChat Inc., (NASDAQ:DATS) went public.  AIkido owns 525,000 shares of DatChat, which it previously purchased for $500,000.00.  As of September 13th, DatChat shares closed at $6.54, well higher than its IPO price and representing a more than 600% return or an additional $3,433,500.00 ad

    9/14/21 9:22:00 AM ET
    $AIKI
    $DATS
    Specialty Chemicals
    Consumer Discretionary
    Telecommunications Equipment
    Telecommunications

    AIkido Pharma Provides Business Update

    NEW YORK, April 5, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided a business update. Anthony Hayes, CEO of AIkido Pharma, stated, "AIkido's primary focus is the commercialization of improved treatments for multiple types of cancer and viral infections through innovative research and development that leverages the power of artificial intelligence and machine learning. Our research partners continue to make progress towards this focus with positive results in ongoing preclinical studies. In addition, through a series of financing transactions over the course of 2020, and the last several months, we are sufficiently capitalized to support our

    4/5/21 9:00:00 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    $AIKI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by AIkido Pharma Inc.

    SC 13D - Dominari Holdings Inc. (0000012239) (Subject)

    12/28/23 4:15:22 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    12/28/23 4:05:18 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    7/6/23 4:30:08 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary